menu search

INRLF / Valneva's Vaccination Valor: A Buy Rating Justified

Valneva's Vaccination Valor: A Buy Rating Justified
Valneva's 1H 2023 revenue declined compared to the previous year, but product sales more than doubled, driven by the recovery in the travel market. The phase 3 trial for VLA15, a Lyme disease vaccine candidate, is progressing well, with plans for official submissions to the FDA and EMA in 2026. Valneva's chikungunya vaccine, VLA1553, awaits PDUFA action by the end of November 2023, with the potential for a Priority Review Voucher valued at $100M. Read More
Posted: Oct 4 2023, 23:45
Author Name: Seeking Alpha
Views: 111499

INRLF News  

Valneva's Vaccination Valor: A Buy Rating Justified

By Seeking Alpha
October 4, 2023

Valneva's Vaccination Valor: A Buy Rating Justified

Valneva's 1H 2023 revenue declined compared to the previous year, but product sales more than doubled, driven by the recovery in the travel market. Th more_horizontal

Pfizer, Valneva announce 'positive' results for Lyme disease vaccine candidate booster shot

By Reuters
September 7, 2023

Pfizer, Valneva announce 'positive' results for Lyme disease vaccine candidate booster shot

Pfizer and French pharmaceutical peer Valneva announced on Thursday that a phase 2 study for its VLA15 Lyme disease vaccine candidate showed a "strong more_horizontal

Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race

By Seeking Alpha
July 18, 2023

Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race

Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due t more_horizontal


Search within

Pages Search Results: